Garg Pushkal
EVP Chief R&D at ALNY
- Sold, on record
- $36.4M
- Dollars the filings state
- Form 4 sales
- 20
- Latest Mar 5, 2026
- Form 144 notices
- 7
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- ALNYALNYLAM PHARMACEUTICALS, INC.EVP Chief R&D
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale ALNYUnusualMar 24, 2025 2025
Sold 9,766 shares at $293.36 ($2.9M)
Garg Pushkal, CMO & EVP Dev & Med Affairs
10b5-1 planSold 32.6% of holdings ($8.8M position)20,221 shares left4.6x usual sizeFiling
- 2 Form 4 sale ALNYRoutineAug 19, 2025 +148 days
Sold 2,851 shares at $455.89 ($1.3M)
Garg Pushkal, EVP Chief R&D
10b5-1 planSold 12.4% of holdings ($10.5M position)20,221 shares left1.5x usual sizeFiling
- 3 Form 4 sale ALNYRoutineOct 3, 2025 +45 days
Sold 5,959 shares at $451.76 ($2.7M)
Garg Pushkal, EVP Chief R&D
10b5-1 planSold 22.8% of holdings ($11.8M position)20,221 shares left2.8x usual sizeFiling
- 4 Form 4 sale ALNYNo planJan 12, 2026 +101 days
Sold 1,510 shares at $362.87 ($548k)
Garg Pushkal, EVP Chief R&D
No 10b5-1 planSold 6.3% of holdings ($8.7M position)22,511 shares left0.6x usual sizeFiling
- 5 Form 4 sale ALNYNo planFeb 13, 2026 +32 days
Sold 2,242 shares at $310.08 ($695k)
Garg Pushkal, EVP Chief R&D
No 10b5-1 planSold 8.3% of holdings ($8.4M position)24,848 shares left1.1x usual sizeFiling
- 6 Form 4 sale ALNYRoutineFeb 27, 2026 +14 days
Sold 4,627 shares at $331.34 ($1.5M)
Garg Pushkal, EVP Chief R&D
10b5-1 planSold 17.3% of holdings ($8.9M position)22,129 shares left2.1x usual sizeFiling
- 7 Form 4 sale ALNYRoutineMar 3, 2026 +4 days
Sold 3,492 shares at $323.63 ($1.1M)
Garg Pushkal, EVP Chief R&D
10b5-1 planSold 13% of holdings ($8.7M position)23,406 shares left1.4x usual sizeFiling
- 8 Form 4 sale ALNYRoutineMar 5, 2026 +2 days
Sold 4,713 shares at $323.53 ($1.5M)
Garg Pushkal, EVP Chief R&D
10b5-1 planSold 20.1% of holdings ($7.6M position)18,693 shares left1.7x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (27)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | Mar 6, 2026 | ALNY | EVP Chief R&D | Form 4 sale | 4,713 | $1.5M | 20.1% | Routine | SEC |
| Mar 3, 2026 | Mar 4, 2026 | ALNY | EVP Chief R&D | Form 4 sale | 3,492 | $1.1M | 13.0% | Routine | SEC |
| Feb 27, 2026 | Mar 2, 2026 | ALNY | EVP Chief R&D | Form 4 sale | 4,627 | $1.5M | 17.3% | Routine | SEC |
| Feb 13, 2026 | Feb 17, 2026 | ALNY | EVP Chief R&D | Form 4 sale | 2,242 | $695k | 8.3% | No plan | SEC |
| Jan 12, 2026 | Jan 14, 2026 | ALNY | EVP Chief R&D | Form 4 sale | 1,510 | $548k | 6.3% | No plan | SEC |
| Oct 3, 2025 | Oct 3, 2025 | ALNY | EVP Chief R&D | Form 4 sale | 5,959 | $2.7M | 22.8% | Routine | SEC |
| Aug 19, 2025 | Aug 19, 2025 | ALNY | EVP Chief R&D | Form 4 sale | 2,851 | $1.3M | 12.4% | Routine | SEC |
| Mar 24, 2025 | Mar 25, 2025 | ALNY | CMO & EVP Dev & Med Affairs | Form 4 sale | 9,766 | $2.9M | 32.6% | Unusual | SEC |
| Mar 4, 2025 | Mar 5, 2025 | ALNY | CMO & EVP Dev & Med Affairs | Form 4 sale | 2,557 | $621k | 9.4% | Routine | SEC |
| Mar 4, 2025 | Mar 4, 2025 | ALNY | Officer | Form 144 notice | 808 | $195k | Notice | SEC | |
| Mar 3, 2025 | Mar 3, 2025 | ALNY | Officer | Form 144 notice | 973 | $240k | Notice | SEC | |
| Feb 28, 2025 | Mar 3, 2025 | ALNY | CMO & EVP Dev & Med Affairs | Form 4 sale | 935 | $226k | 6.7% | No plan | SEC |
| Feb 18, 2025 | Feb 18, 2025 | ALNY | Officer | Form 144 notice | 1,548 | $398k | Notice | SEC | |
| Feb 18, 2025 | Feb 18, 2025 | ALNY | CMO & EVP Dev & Med Affairs | Form 4 sale | 3,109 | $788k | 20.6% | Routine | SEC |
| Jan 27, 2025 | Jan 29, 2025 | ALNY | CMO & EVP Dev & Med Affairs | Form 4 sale | 52,592 | $15M | 81.4% | Unusual | SEC |
| Jan 27, 2025 | Jan 27, 2025 | ALNY | Officer | Form 144 notice | 52,592 | $15M | Notice | SEC | |
| Dec 12, 2024 | Dec 13, 2024 | ALNY | CMO & EVP Dev & Med Affairs | Form 4 sale | 1,752 | $440k | 10.0% | Routine | SEC |
| Dec 12, 2024 | Dec 12, 2024 | ALNY | Officer | Form 144 notice | 1,752 | $447k | Notice | SEC | |
| Nov 26, 2024 | Nov 27, 2024 | ALNY | CMO & EVP Dev & Med Affairs | Form 4 sale | 1,682 | $422k | 8.8% | No plan | SEC |
| Jun 25, 2024 | Jun 26, 2024 | ALNY | CMO & EVP Dev & Med Affairs | Form 4 sale | 2,103 | $486k | 11.9% | No plan | SEC |
| Feb 28, 2024 | Feb 29, 2024 | ALNY | CMO & EVP Dev & Med Affairs | Form 4 sale | 574 | $89k | 6.2% | No plan | SEC |
| Feb 16, 2024 | Feb 20, 2024 | ALNY | CMO & EVP Dev & Med Affairs | Form 4 sale | 1,308 | $194k | 15.1% | No plan | SEC |
| Aug 7, 2023 | Aug 7, 2023 | ALNY | CMO & EVP Dev & Med Affairs | Form 4 sale | 7,627 | $1.4M | 63.7% | Unusual | SEC |
| Aug 7, 2023 | Aug 7, 2023 | ALNY | Officer | Form 144 notice | 4,166 | $766k | Notice | SEC | |
| Apr 28, 2023 | Apr 28, 2023 | ALNY | CMO & EVP Dev & Med Affairs | Form 4 sale | 4,294 | $846k | 49.7% | Unusual | SEC |
| Apr 28, 2023 | Apr 28, 2023 | ALNY | Officer | Form 144 notice | 2,455 | $479k | Notice | SEC | |
| Mar 3, 2023 | Mar 7, 2023 | ALNY | CMO & EVP Dev & Med Affairs | Form 4 sale | 18,072 | $3.6M | 80.6% | Unusual | SEC |